Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
1(13%)
Results Posted
125%(5 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
3
38%
Ph phase_3
3
38%

Phase Distribution

2

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
3(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 23 (37.5%)
Phase 33 (37.5%)

Trials by Status

terminated225%
active_not_recruiting113%
completed450%
not_yet_recruiting113%

Recent Activity

1 active trials
Showing 5 of 8
not_yet_recruitingphase_2

Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia

NCT07154485
active_not_recruitingphase_3

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

NCT03522246
completedphase_2

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

NCT03867097
completedphase_3

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

NCT04040322
completedphase_1

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

NCT05640531
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07154485Phase 2

Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia

Not Yet Recruiting
NCT03522246Phase 3

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Active Not Recruiting
NCT03867097Phase 2

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Completed
NCT04040322Phase 3

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

Completed
NCT05640531Phase 1

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

Completed
NCT02377466Phase 3

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

Terminated
NCT00682565Phase 2

PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina

Completed
NCT01162889Phase 1

Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8